Search Results - "Os, Steve"

Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study by Shore, Neal D, Dr, Chowdhury, Simon, MD, Villers, Arnauld, Prof, Klotz, Laurence, MD, Siemens, D Robert, Prof, Phung, De, BSc, van Os, Steve, MD, Hasabou, Nahla, MD, Wang, Fong, MD, Bhattacharya, Suman, PhD, Heidenreich, Axel, Prof

“…Summary Background Enzalutamide is an oral androgen-receptor inhibitor that has been shown to improve survival in two placebo-controlled phase 3 trials, and is…”
Get full text

Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial by Ulys, Albertas, Jankevicus, Feliksas, Jievaltas, Mindaugas, Venckus, Raimundas, Auskalnis, Stasys, Kardelis, Zygimantas, Barisiene, Marija, MacLean, Carol M., Os, Steve, Larsen, Finn

“…Background Teverelix drug product (DP) is a novel injectable gonadotropin‐releasing hormone antagonist. Methods An adaptive phase 2, open‐label, multicenter…”
Get full text

A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk by Sannala, Chenna Keshava Reddy, MacLean, Carol, Larsen, Finn, Os, Steve, Jadhav, Pravin, Shore, Neal, Morgans, Alicia K., Okwuosa, Tochukwu, Gobburu, Joga

“…Teverelix drug product (DP) is a parenteral gonadotropin‐releasing hormone (GnRH) antagonist that has been successfully tested in phase 2 trials for…”
Get full text

Development of enzalutamide for metastatic castration-resistant prostate cancer by Bhattacharya, Suman, Hirmand, Mohammad, Phung, De, van Os, Steve

“…Prostate cancer is the most prevalent cancer among men in the Western world and a leading cause of cancer‐related death among men. Within 5 years of initial…”
Get full text

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial by Kenemans, Peter, Prof, Bundred, Nigel J, Prof, Foidart, Jean-Michel, Prof, Kubista, Ernst, Prof, von Schoultz, Bo, Prof, Sismondi, Piero, Prof, Vassilopoulou-Sellin, Rena, Prof, Yip, Cheng Har, Prof, Egberts, Jan, MSc, Mol-Arts, Mirjam, MD, Mulder, Roel, van Os, Steve, MD, Beckmann, Matthias W, Prof

“…Summary Background Vasomotor symptoms and bone loss are complications frequently induced by adjuvant treatment for breast cancer. Tibolone prevents both…”
Get full text

Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies by MacLean, Carol M, Ulys, Albertas, Jankevičius, Feliksas, Saladžinskas, Žilvinas, van Os, Steve, Larsen, Finn

“…Teverelix drug product (DP) is a gonadotropin-releasing hormone antagonist in development for the treatment of patients with prostate cancer in whom androgen…”
Get full text

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial by Armstrong, Andrew J., Lin, Ping, Tombal, Bertrand, Saad, Fred, Higano, Celestia S., Joshua, Anthony M., Parli, Teresa, Rosbrook, Brad, van Os, Steve, Beer, Tomasz M.

“…In the PREVAIL study, enzalutamide significantly improved clinical outcomes versus placebo in patients with chemotherapy-naïve metastatic castration-resistant…”
Get full text

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study by Beer, Tomasz M, Armstrong, Andrew J, Rathkopf, Dana, Loriot, Yohann, Sternberg, Cora N, Higano, Celestia S, Iversen, Peter, Evans, Christopher P, Kim, Choung-Soo, Kimura, Go, Miller, Kurt, Saad, Fred, Bjartell, Anders S, Borre, Michael, Mulders, Peter, Tammela, Teuvo L, Parli, Teresa, Sari, Suha, van Os, Steve, Theeuwes, Ad, Tombal, Bertrand

“…Abstract Enzalutamide significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) among men with chemotherapy-naïve…”
Get full text

Teverelix is a potential treatment option for the prevention of acute urinary retention recurrence in men suffering from benign prostatic hyperplasia by Ulys, Albertas, Černiauskienė, Aušra, Geavlete, Petrișor, Larsen, Finn, MacLean, Carol M, van Os, Steve

“…To evaluate the efficacy and safety of teverelix in treatment naïve patients aged over 50 years with symptomatic benign prostatic hyperplasia (BPH) and lower…”
Get full text

Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial by Siemens, D. Robert, Klotz, Laurence, Heidenreich, Axel, Chowdhury, Simon, Villers, Arnauld, Baron, Benoit, van Os, Steve, Hasabou, Nahla, Wang, Fong, Lin, Ping, Shore, Neal D.

“…Enzalutamide significantly prolonged median progression-free survival vs bicalutamide in chemotherapy naïve men with metastatic castration resistant prostate…”
Get full text

Efficacy and safety of enzalutamide vs bicalutamide in European and North American men participating in the TERRAIN trial by Chowdhury, Simon, Shore, Neal D., Villers, Arnauld, Klotz, Laurence, Siemens, D. Robert, Baron, Benoit, van Os, Steve, Hasabou, Nahla, Wang, Fong, Forer, David, Heidenreich, Axel

“…Abstract only…”
Get full text

TERRAIN by Chowdhury, Simon, Heidenreich, Axel, Villers, Arnauld, Klotz, Laurence, Siemens, D. Robert, Phung, De, Wang, Fong, Forer, David, Van Os, Steve, Shore, Neal D.

“…Abstract only…”
Get full text

PII-LBA4 TERRAIN TRIAL: PROSTATE-SPECIFIC ANTIGEN KINETICS AND QUALITY OF LIFE RESULTS OF ENZALUTAMIDE VERSUS BICALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER by Shore, Neal, Heidenreich, Axel, Villers, Arnauld, Klotz, Laurence, Hussain, Maha, Karsh, Lawrence, van Os, Steve, Baron, Benoit, Wang, Fong, Forer, David, Chowdhury, Simon, Siemens, Robert D

Get full text

Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study by Beer, Tomasz M., Armstrong, Andrew J., Sternberg, Cora N., Higano, Celestia S., Rathkopf, Dana E., Loriot, Yohann, Saad, Fred, Joshua, Anthony M., De Bono, Johann Sebastian, Venner, Peter M., Carles, Joan, Mainwaring, Paul N., Evans, Christopher P., Parli, Teresa, Mansbach, Harry H., Bhattacharya, Suman, Van Os, Steve, Phung, De, TOMBAL, Bertrand F.

“…Abstract only…”
Get full text

Low-dose tibolone (1.25 mg/d) does not affect muscle strength in older women by Ribom, Eva L., Svensson, Peter, van Os, Steve, Larsson, Marita, Naessen, Tord

“…OBJECTIVE:More than 50% of all fractures occur in people without osteoporosis. Hormone therapy increases bone density, improves postural balance, and reduces…”
Get full text

Endometrial Effects of Tibolone in Elderly, Osteoporotic Women by Ettinger, Bruce, Kenemans, Peter, Johnson, Susan R., Mol-Arts, Mirjam, Van Os, Steve, Seifert, Wilfried, Verweij, Pierre J.M., Cummings, Steven R.

“…To investigate endometrial effects of tibolone administered to postmenopausal women for 3 years. Postmenopausal women (N=3,519) aged 60-85 years (mean 68…”
Get full text

Tibolone low dose (1.25 mg/d) therapy and postural balance in elderly women by Naessen, Tord, Lindmark, Birgitta, Larsen, Hans Christian, van Os, Steve, Larsson, Marita

“…Abstract Most hip fractures occur in subjects without osteoporosis and are associated with a fall. Conventional menopausal hormone therapy (HT) improves…”
Get full text